Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction: a pharmacovigilance analysis

作者：Mengting Shen, Luyao He, Pei Chen, Li Zhang, Duan Zeng, Yan Li, Huafang Li · 发表于：Sexual Medicine · 年份：2026 · DOI：10.1093/sexmed/qfag008 · 研究领域：Pharmacovigilance and Adverse Drug Reactions、Treatment of Major Depression、Sexual function and dysfunction studies

Background: In clinical practice, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) remain commonly used owing to their proven antidepressant efficacy, however, they are also associated with a considerable risk of sexual adverse effects. Aim: To examine the relationship between individual SSRIs/SNRIs and distinct sexual dysfunction symptoms. Methods: Using the Food and Drug Administration's Adverse Event Reporting System (FAERS) database, we performed a pharmacovigilance analysis of adverse drug events. Disproportionality signals were detected using reporting odds ratios (RORs) and information components (ICs), with Bayesian shrinkage transformation applied to mitigate random variability. Outcomes: The primary outcome indicators are RORs and ICs, which were employed to evaluate the association between SSRIs and SNRIs and the development of sexual dysfunction. Results: Comparative analysis of antidepressant-related adverse events in the FAERS database showed that while sexual dysfunction was associated with all studied SSRIs/SNRIs (sertraline, citalopram/escitalopram, paroxetine, fluoxetine, venlafaxine, and duloxetine), symptom profiles varied markedly. Sertraline presented the most diverse array of sexual dysfunction manifestations, contrasting with duloxetine's relatively restricted adverse effect profile. Clinical Implications: This study provides valuable real-world evidence to assist clinicians in optimizing antidepr...